{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T21:41:24Z","timestamp":1761169284939,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jval.2020.04.1837","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T03:33:24Z","timestamp":1599536004000},"page":"1281-1285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial"],"prefix":"10.1016","volume":"23","author":[{"given":"John D.","family":"Reveille","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akgun","family":"Ince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric K.H.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth C.","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilianne","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim Hung","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane D.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenglong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2020.04.1837_bib1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/MAJ.0b013e318294457f","article-title":"The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States","volume":"345","author":"Reveille","year":"2013","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jval.2020.04.1837_bib2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/1529-0131(199908)12:4<247::AID-ART3>3.0.CO;2-H","article-title":"Health-related quality of life in ankylosing spondylitis: a survey of 175 patients","volume":"12","author":"Ward","year":"1999","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jval.2020.04.1837_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3899\/jrheum.170487","article-title":"Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE study","volume":"45","author":"Deodhar","year":"2018","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jval.2020.04.1837_bib4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36): conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2020.04.1837_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol--a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.jval.2020.04.1837_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.62.1.20","article-title":"Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis","volume":"62","author":"Doward","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jval.2020.04.1837_bib7","first-page":"2286","article-title":"A\u00a0new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jval.2020.04.1837_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00019053-200422001-00004","article-title":"Patient-reported outcomes and their role in the assessment of rheumatoid arthritis","volume":"22","author":"Lubeck","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.04.1837_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/009286150303700105","article-title":"Practical guidelines for assessing the clinical significane of health-related quality of life changes within clinical trials","volume":"37","author":"Sloan","year":"2003","journal-title":"Drug Inf J"},{"key":"10.1016\/j.jval.2020.04.1837_bib10","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/rheumatology\/41.11.1295","article-title":"Disease-specific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness","volume":"41","author":"Haywood","year":"2002","journal-title":"Rheumatology (Oxford)"},{"year":"1994","series-title":"Interpretation: Norm-Based. SF-36 Physical and Mental Health Summary Scales: A User's Manual","author":"Ware","key":"10.1016\/j.jval.2020.04.1837_bib11"},{"key":"10.1016\/j.jval.2020.04.1837_bib12","series-title":"Self-Reported Population Health: An International Perspective Based on EQ-5D","article-title":"Population norms for the EQ-5D","author":"Janssen","year":"2014"},{"key":"10.1016\/j.jval.2020.04.1837_bib13","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2020.04.1837_bib14","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/art.22887","article-title":"Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study","volume":"57","author":"Davis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jval.2020.04.1837_bib15","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/acr.22594","article-title":"Impact of certolizumab pegol on patient-reported outcomes in patients with axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jval.2020.04.1837_bib16","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/art.21330","article-title":"Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy","volume":"53","author":"Davis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jval.2020.04.1837_bib17","doi-asserted-by":"crossref","first-page":"R103","DOI":"10.1186\/ar2306","article-title":"The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases","volume":"9","author":"Han","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jval.2020.04.1837_bib18","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jval.2020.04.1837_bib19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0277-9536(96)00221-3","article-title":"Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango)","volume":"44","author":"Charles","year":"1997","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.jval.2020.04.1837_bib20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2147\/PPA.S121032","article-title":"Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn's disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis","volume":"11","author":"Bolge","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jval.2020.04.1837_bib21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/BOR.0000000000000591","article-title":"Patient preferences for rheumatoid arthritis treatment","volume":"31","author":"Hsiao","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jval.2020.04.1837_bib22","first-page":"93","article-title":"Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis","volume":"8","author":"Huynh","year":"2014","journal-title":"Patient Prefer Adherence"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520322014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520322014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:20:21Z","timestamp":1761096021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301520322014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1098301520322014"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.04.1837","relation":{},"ISSN":["1098-3015"],"issn-type":[{"type":"print","value":"1098-3015"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.04.1837","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}